The latest research & treatment news about Hepatitis C infection, diagnosis, symptoms and treatment.
After just three days of a Phase 1b trial, Vertex's VX-222 is asserting itself as a possible contender to partner with telaprevir for a new Hepatitis C combination therapy regimen.
Continue reading »Learn about the mid-trial results of PSI-7977's effectiveness against Hepatitis C.
Continue reading »Results of the PROVE3 trial found that drug regimens using telaprevir were more effective against Hepatitis C than regimens without telaprevir in both treatment naïve patients and previous treatment non-responders.
Continue reading »An innovative substance with an obvious similarity to a common liver support supplement begins a Phase II clinical trial to protect the livers of those with Hepatitis C.
Continue reading »Upon finding that Isis-11 binds to a spot on the Hepatitis C virus needed for viral replication, researchers may have discovered a new structure for future Hepatitis C treatments.
Continue reading »Based on currently available data and expert opinions, a research and advisory firm projects that the next decade will witness triple and quadruple therapies as the gold standard for treating Hepatitis C.
Continue reading »Zalbin is a Hepatitis C drug in development that could lead to the highly desired monthly or bi-monthly dosing.
Continue reading »Combined with interferon and ribavirin, clinical trials on Vertex's telaprevir demonstrate twice the success rate in clearing Hepatitis C in half the time as traditional combination therapy. While this alone is exciting, Vertex is exploring a range of drug combination options for battling the Hepatitis C virus.
Continue reading »Hepatitis C drug candidates ABT-450, ABT-333 and ABT-072 move into Phase II testing.
Continue reading »Novartis licenses alisporivir, a new drug that is currently in Phase IIb development for the treatment of Hepatitis C.
Continue reading »Inside you'll discover:
You'll also receive the latest news and information to support liver health.
Rest assured, we will not rent your email to anyone.
You should receive your email with links to the reports shortly. If you do not, please check your spam/junk folder.
If you still haven't received our email after a few minutes, please feel free to contact us.
Close Window
